Key result
Hypoglycemia unawareness in T1D is linked to reduced beta-adrenergic sensitivity, requiring ~88% higher isoproterenol doses.
Why the study?
Do subjects with type 1 diabetes and hypoglycemia unawareness have reduced beta-adrenergic sensitivity compared to those with awareness?
Observational (n=21)
Do subjects with type 1 diabetes and hypoglycemia unawareness have reduced beta-adrenergic sensitivity compared to those with awareness?
Subjects with type 1 diabetes and hypoglycemia unawareness have reduced beta-adrenergic sensitivity, which may contribute to impaired adrenergic warning symptoms during hypoglycemia.
Answers are grounded in this paper and cite their sources.
May explain lost adrenergic warnings in type 1 diabetes hypoglycemia unawareness; hypothesis-generating and requires prospective confirmation before clinical consideration.
OBJECTIVE: We tested the hypothesis that impaired tissue sensitivity to catecholamines contributes to hypoglycemia unawareness in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A total of 21 subjects with type 1 diabetes underwent a standardized insulin infusion protocol to produce a stepwise decrease in plasma glucose to 45-min plateaus of 4.3, 3.6, 3.0, and 2.3 mmol/l. Glycemic thresholds, maximum responses for adrenergic and neuroglycopenic symptoms, and counterregulatory hormones were determined. Patients were classified as hypoglycemia unaware if the initiation of adrenergic symptoms occurred at a plasma glucose level 2 SD below that of nondiabetic volunteers. beta-Adrenergic sensitivity was measured as the dose of isoproterenol required to produce an increment in heart rate of 25 beats per minute above baseline (I25) in resting subjects. RESULTS: Subjects with type 1 diabetes and hypoglycemia unawareness experienced the onset of adrenergic symptoms at a lower plasma glucose level than did those with awareness (2.5+/-0.1 vs. 3.7+/-0.1 mmol/l, P < 0.001), whereas neuroglycopenic symptoms occurred at similar glucose levels (2.7+/-0.2 vs. 2.8+/- 0.1 mmol/l). The plasma glucose levels for counterregulatory hormone secretion (epinephrine 2.9+/-0.2 vs. 4.1+/-0.2 mmol/l; norepinephrine 2.7+/-0.1 vs. 3.2+/-0.2 mmol/l; cortisol 2.5+/-0.2 vs. 3.3+/-0.2 mmol/l, P < 0.01) were also lower in subjects with unawareness. The maximal epinephrine (1,954+/-486 vs. 5,332+/- 1,059 pmol/l, P < 0.01), norepinephrine (0.73 +/- 0.14 vs. 1.47+/-0.21 nmol/l, P = 0.04), and cortisol (276+/-110 vs. 579+/-83 nmol/l, P < 0.01) responses were reduced in the unaware group. I25 was greater in unaware subjects than in subjects without unawareness (1.5+/-0.3 vs. 0.8+/-0.2 microg), where I25 was not different from that of controls (0.8 +/-0.2 microg). CONCLUSIONS: We conclude that subjects with type 1 diabetes and hypoglycemia unawareness have reduced beta-adrenergic sensitivity, which may contribute to their impaired adrenergic warning symptoms during hypoglycemia.
No takes yet. Share an insight, caveat, or question.
Korytkowski et al. (1998) conducted an observational in Type 1 diabetes and hypoglycemia unawareness (n=21). Hypoglycemia unawareness vs. Type 1 diabetes without hypoglycemia unawareness was evaluated on beta-Adrenergic sensitivity (I25, dose of isoproterenol required for a 25 bpm heart rate increment). Hypoglycemia unawareness in type 1 diabetes was associated with reduced beta-adrenergic sensitivity, requiring a higher isoproterenol dose to increase heart rate.
Synapse has enriched 10 related papers. Consider them for comparative context: